Skip to main content
. Author manuscript; available in PMC: 2012 Jul 15.
Published in final edited form as: Cancer. 2011 Jan 18;117(14):3163–3172. doi: 10.1002/cncr.25891

Figure 4.

Figure 4

Representative effect of low doses of interleukin-2 (IL-2) in combination with hRS7 (2 μg/ml) on ADCC against USPC ARK-2 primary cell line (Effectors to target ratio 50 : 1). PBL from healthy donors were incubated for 5 hours in the presence of 100 IU/ml of IL-2. hRS7-mediated ADCC was significantly increased in the presence of low doses of IL-2. No significant increase in cytotoxicity was detected after 5 hours IL-2 treatment in the absence of hRS7 or in the presence of the Rituximab isotype control mAb.